BioCentury | Aug 10, 2009
Financial News

Xtent financial update

...said it will voluntarily delist its shares from NASDAQ effective on about Aug. 27. *** Xtent Inc....
BioCentury | Aug 10, 2009
Company News

Xtent cardiovascular news

...30, Xtent had $10 million in cash and a six-month operating loss of $12 million. Xtent Inc....
BioCentury | Mar 30, 2009
Clinical News

Custom NX DES System regulatory update

...mm stent lengths. The company did not disclose when it expects to launch the system. Xtent Inc....
BioCentury | Jan 7, 2008
Clinical News

Custom NX regulatory update

...treat coronary artery disease (CAD). Xtent plans to launch the product in Europe in 2H08. Xtent Inc....
BioCentury | Oct 29, 2007
Clinical News

Custom NX: Additional pilot trial data

...28). The trial enrolled 69 patients with long lesions and 31 patients with 2 lesions. Xtent Inc....
BioCentury | Oct 29, 2007
Clinical News

Custom NX: Pilot trial data

...events from 8 months to 2 years. Restenosis and late stent thrombosis rates were zero. Xtent Inc....
BioCentury | Aug 13, 2007
Clinical News

Custom NX: Completed enrollment in pilot trial

...patients with single focal, long or multiple lesions in the pilot European CUSTOM III trial. Xtent Inc....
BioCentury | May 28, 2007
Clinical News

Custom NX: Pilot trial data

...and 31 patients with 2 lesions. Data were presented at the EuroPCR meeting in Barcelona. Xtent Inc....
BioCentury | Apr 2, 2007
Finance

IPO performance

...BiolineRx (Tel Aviv:BLRX) 2/7/07 $49.9 $113.1 $89.9 -21% Oculus (OCLS) 1/24/07 $24.2 $91.4 $67.8 -26% Xtent...
BioCentury | Mar 19, 2007
Analyst Picks & Changes

Analyst picks & changes

...guidance. XOMA expects FY07 revenue to come in at $57.5-$60.5M, a 95-105% increase over FY06. Xtent...
Items per page:
1 - 10 of 11
BioCentury | Aug 10, 2009
Financial News

Xtent financial update

...said it will voluntarily delist its shares from NASDAQ effective on about Aug. 27. *** Xtent Inc....
BioCentury | Aug 10, 2009
Company News

Xtent cardiovascular news

...30, Xtent had $10 million in cash and a six-month operating loss of $12 million. Xtent Inc....
BioCentury | Mar 30, 2009
Clinical News

Custom NX DES System regulatory update

...mm stent lengths. The company did not disclose when it expects to launch the system. Xtent Inc....
BioCentury | Jan 7, 2008
Clinical News

Custom NX regulatory update

...treat coronary artery disease (CAD). Xtent plans to launch the product in Europe in 2H08. Xtent Inc....
BioCentury | Oct 29, 2007
Clinical News

Custom NX: Additional pilot trial data

...28). The trial enrolled 69 patients with long lesions and 31 patients with 2 lesions. Xtent Inc....
BioCentury | Oct 29, 2007
Clinical News

Custom NX: Pilot trial data

...events from 8 months to 2 years. Restenosis and late stent thrombosis rates were zero. Xtent Inc....
BioCentury | Aug 13, 2007
Clinical News

Custom NX: Completed enrollment in pilot trial

...patients with single focal, long or multiple lesions in the pilot European CUSTOM III trial. Xtent Inc....
BioCentury | May 28, 2007
Clinical News

Custom NX: Pilot trial data

...and 31 patients with 2 lesions. Data were presented at the EuroPCR meeting in Barcelona. Xtent Inc....
BioCentury | Apr 2, 2007
Finance

IPO performance

...BiolineRx (Tel Aviv:BLRX) 2/7/07 $49.9 $113.1 $89.9 -21% Oculus (OCLS) 1/24/07 $24.2 $91.4 $67.8 -26% Xtent...
BioCentury | Mar 19, 2007
Analyst Picks & Changes

Analyst picks & changes

...guidance. XOMA expects FY07 revenue to come in at $57.5-$60.5M, a 95-105% increase over FY06. Xtent...
Items per page:
1 - 10 of 11